New-Modality Drugs Behind Today’s Big Headlines
How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets.
A lot has been happening lately across biopharma spanning massive deals and landmark approvals. Madrigal Pharmaceuticals has signed a $4.4B agreement with China’s Ribo Life Science to co-develop six preclinical siRNA therapies targeting metabolic dysfunction–associated steatohepatitis (MASH). Earlier, during the JPM week, AbbVie announced a $5.6B deal with RemeGen for a PD-1xVEGF bispecific antibody aimed at treating solid tumors. Meanwhile, Eli Lilly acquired CAR-T developer Orna for $2.4B, and the FDA approved the first oral GLP-1 therapy for weight loss, developed by Novo Nordisk.
At first glance, these headlines span different companies and medical areas. But they share a common thread: each centers on advanced therapeutic modalities (ATMs)—a new generation of medicines that go beyond the limits of conventional drugs.

Number of products in the pipelines over 2023-2025, adapted from BCG data
According to BCG, eight of the top ten best-selling biopharma products in 2025 are new-modality drugs, and the global pipeline value for these therapies has reached $197B. ATMs are becoming a more established part of the industry and are noticeably contributing to its growth.
In this issue: Reject Tradition, Embrace Modernity — A World In Between — Antibodies — Proteins and Peptides — Cell Therapies — Gene Therapies — Nucleic Acids — Targeted Protein Degraders — Lookahead
Read this Pro article free
Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.
Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.